This article is more than 5 years old. Information may no longer be current.
Allergan receives FDA approval for Trivaris injectable triamcinolone suspension
Click Here to Manage Email Alerts
IRVINE, Calif. — The U.S. Food and Drug Administration has approved Allergan's Trivaris injectable 80 mg/mL triamcinolone acetonide suspension for treating retinal disease, the company announced in a press release.
Trivaris is a synthetic glucocorticoid corticosteroid with anti-inflammatory properties that can be injected intravitreally for treating sympathetic ophthalmia, temporal arteritis, uveitis and other ocular inflammatory conditions that may not respond to topical corticosteroids, according to the release.
"Trivaris marks the first approval for Allergan resulting from our strategic focus on the development of therapies for back-of-the-eye diseases, and we remain committed to bringing forth innovative new treatments for patients suffering from retinal diseases," Scott Whitcup, MD, Allergan's executive vice president of research and development, said in the release.